Major Depressive Disorder News and Research

RSS

Major Depressive Disorder (MDD) is a psychiatric condition characterized by depressed mood or anhedonia (significant loss of interest or pleasure). The condition affects more than 15.7 million adults and approximately 3 million adolescents (aged 13 to 17 years) in the USA each year.

Labopharm to present its novel trazodone formulation data

Labopharm Inc. today announced that three separate posters will be presented at three upcoming internationally prestigious medical meetings showcasing data on its novel trazodone formulation.

10 Sep 2009

Research study examines the depression rate in chronic kidney disease patients

One in five patients with chronic kidney disease is depressed, even before beginning long-term dialysis therapy or developing end-stage renal disease, UT Southwestern Medical Center researchers have found.

9 Sep 2009

New research on post-traumatic stress disorder to be presented at MHRF

New research on post-traumatic stress disorder (PTSD) is being presented this week at the Military Health Research Forum (MHRF), a scientific conference hosted by the Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP). Depending on the conflict in which they served, 10 to 30 percent of soldiers who have spent time in war zones experience the debilitating and life-altering symptoms of post-traumatic stress disorder (PTSD).

2 Sep 2009

Psychological therapy for breast cancer patients reduces blood inflammation levels

A psychological intervention for newly diagnosed breast cancer patients with symptoms of depression not only relieves patients' depression but also lowers indicators of inflammation in the blood.

1 Sep 2009

IntelGenx Technologies shareholder conference call to update shareholders on CPI-300

Horst G. Zerbe, President and CEO of IntelGenx Technologies Corp. ("IntelGenx") will be holding a shareholder conference call to update shareholders on the company's CPI-300 product and remark on related legal proceedings. The call will be held on Tuesday September 1, 2009 at 2.30 p.m. Eastern Standard Time.

31 Aug 2009

Thickening of neck arteries in healthy middle-aged women with feelings of hopelessness

Healthy middle-aged women with feelings of hopelessness appear to experience thickening of the neck arteries, which can be a precursor to stroke, according to new research out of the University of Minnesota Medical School.

27 Aug 2009

Decreased cravings for pleasure may be at root of a core symptom of major depressive disorder

Decreased motivation to seek and experience pleasurable experiences, known as anhedonia, is a primary symptom of major depressive disorder. Anhedonia is less responsive to many antidepressants and often persists after other symptoms of depression subside. However, understanding the different components of anhedonia - the desire to obtain something pleasurable versus experiencing pleasure - has been difficult for researchers to determine in humans.

12 Aug 2009

Depression among preschoolers - may continue into childhood

Depression among preschoolers appears to be a continuous, chronic condition rather than a transient developmental stage, according to a report in the August issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

4 Aug 2009

Depression missed and misidentified

A meta-analysis of more than 50,000 patients has shown that general practitioners (GPs) have great difficulty separating those with and without depression, with substantial numbers of missed and misidentified.

30 Jul 2009

Major depressive disorder redefined

Researchers from Rhode Island Hospital's department of psychiatry propose that the definition for major depressive disorder (MDD) should be shortened to include only the mood and cognitive symptoms that have been part of the definition in the Diagnostic and Statistical Manual of Mental Disorders (DSM) for the past 35 years.

24 Jul 2009

Light therapy as a treatment for sexual dysfunctions

Although we are still far from knowing exactly where and how the pineal suppressive role is exerted, the fact that the gland exerts an inhibitory function on the reproductive axis is widely accepted. In fact, the pineal seems to exert its hormonal effect at different levels of the reproductive axis, both at the hypothalamic-pituitary level and at the gonadal level, where melatonin receptors have also been found.

9 Jun 2009

Lilly resubmits Cymbalta supplemental NDA for chronic pain to FDA

Eli Lilly and Company has resubmitted its supplemental New Drug Application (sNDA) for Cymbalta (duloxetine HCl) for the management of chronic pain to the U.S. Food and Drug Administration (FDA).

3 Jun 2009

Negative mood-related drinking may mean vulnerability for major depression and alcohol dependence

Major depression (MD) and alcohol dependence (AD) co-occur in individuals and within families at higher rates than expected by chance. This study looked at how mood-related drinking motives may explain the overlapping familial risk for MD and AD. Findings suggest that individuals with strong mood-related drinking motives, especially those based on negative feelings, may be vulnerable to developing both MD and AD.

12 May 2009

Participants in antidepressant drug trials are atypical patients

One reason antidepressant medication treatments do not work as well in real life as they do in clinical studies could be the limited type of study participants selected, researchers at UT Southwestern Medical Center have found.

12 May 2009

GSK to divest U.S. rights for Wellbutrin XL to Biovail

GlaxoSmithKline has announced that it has entered into an agreement to divest full commercial rights to Wellbutrin XL in the United States to Biovail International Laboratories SRL, a subsidiary of Biovail Corporation, for $510 million (euro 340 million). The agreement is subject to Hart-Scott-Rodino regulatory clearance in the United States.

6 May 2009

Aussies wanted for international groundbreaking study on depression

Australians researchers have put out a call for 400 people to take part in a study on depression.

26 Apr 2009

In the ICU, use of benzodiazepines, other factors may predict severity of post-stay depression

Psychiatrists and critical care specialists at Johns Hopkins have begun to tease out what there is about a stay in an intensive care unit (ICU) that leads so many patients to report depression after they go home.

12 Apr 2009

Seroquel XR supplemental NDA recommended for approval

The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) conducted a review of the safety and efficacy of supplemental new drug applications (sNDA) for Seroquel XR (quetiapine fumarate) extended-release tablets proposed for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD).

9 Apr 2009

p11 protein may lead to faster acting antidepressants

Research conducted by Nobel laureate Paul Greengard, Medical Director of The Michael Stern Parkinson's Research Center at The Rockefeller University, Dr. Jennifer L. Warner-Schmidt in New York and colleagues in Sweden, demonstrated in the Journal of Neuroscience that the brain protein called p11 could lead pharmaceutical companies to develop anti-depression drugs that begin working within hours or days rather than the weeks or even months required by current drugs.

23 Mar 2009

FDA approves Symbyax for treatment-resistant depression

The U.S. Food and Drug Administration (FDA) has approved a new indication for Symbyax (olanzapine and fluoxetine HCl capsules), Eli Lilly and Company has announced.

23 Mar 2009